Antiangiogenic therapy targeting vascular endothelial growth factor and its receptors (VEGFR) has revolutionized the treatment of various malignancies (renal cell carcinoma [RCC], endometrial cancer, thyroid cancer, colorectal cancer). Here, KDR is linked to renal cell carcinoma.